The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner
Abstract
Survivin, a human inhibitor of apoptosis protein (IAP), plays an important role in both cell cycle regulation and inhibition of apoptosis. Survivin is expressed in cells during the G2/M phase of the cell cycle, followed by rapid decline of both mRNA and protein levels at the G1 phase. It has been suggested that cell cycle-dependent expression of survivin is regulated at the transcriptional level. In this study we demonstrate involvement of the ubiquitin-proteasome pathway in post-translational regulation of survivin. Survivin is a short-lived protein with a half-life of about 30 minutes and proteasome inhibitors greatly stabilise survivin in vivo. Expression of the survivin gene under the control of the CMV promoter cannot block cell cycle-dependent degradation of the protein. Proteasome inhibitors can block survivin degradation during the G1 phase and polyubiquitinated derivatives can be detected in vivo. Mutation of critical amino acid residues within the baculovirus IAP repeat (BIR) domain or truncation of the N terminus or the C terminus sensitises survivin to proteasome degradation. Together, these results indicate that the ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner and structural changes greatly destabilise the survivin protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
A generic protein purification method for protein complex characterization and proteome exploration
Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., & Séraphin, B. (1999) · Nature Biotechnology · doi:10.1038/13732 · Cited by 2,707
IAP family proteins---suppressors of apoptosis
Deveraux, Q. L., & Reed, J. C. (1999) · Genes & Development · doi:10.1101/gad.13.3.239 · Cited by 2,551
β-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
The ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Deveraux, Q. L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2215 · Cited by 1,388
Cited by
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Survivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0746 · Cited by 765
Aoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
The molecular basis and potential role of survivin in cancer diagnosis and therapy
Altieri, D. C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02243-2 · Cited by 412
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Song, Z., Yao, X., & Wu, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300957200 · Cited by 363
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016) · Journal of Cancer · doi:10.7150/jca.13332 · Cited by 347
A p34cdc2 survival checkpoint in cancer
O'Connor, D. S., Wall, N. R., Porter, A. C. G., & Altieri, D. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00084-3 · Cited by 315
Survivin study: What is the next wave?
Li, F. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10327 · Cited by 309
Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172734 · Cited by 267
Metadata
- Authors
- Zhao, J., Tenev, T., Martins, L. M., Downward, J., & Lemoine, N. R.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2000-12-01
- Volume
- 113
- Issue
- 23
- Pages
- 4363-4371
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W1863167619
- Cited by
- 277
- References
- 40
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.